{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:41:44Z","timestamp":1782315704890,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1053\/j.ajkd.2023.04.016","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T11:21:20Z","timestamp":1690802480000},"page":"772-775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition"],"prefix":"10.1053","volume":"82","author":[{"given":"Jami","family":"Kronick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal Y.","family":"Gabril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7152-6163","authenticated-orcid":false,"given":"Andrew A.","family":"House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.ajkd.2023.04.016_bib1","first-page":"1060","article-title":"Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs","volume":"18","author":"Vekeman","year":"2015","journal-title":"J\u00a0Med Econ"},{"issue":"2","key":"10.1053\/j.ajkd.2023.04.016_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000448293","article-title":"Review of the tuberous sclerosis renal guidelines from the 2012 Consensus Conference: current data and future study","volume":"134","author":"Kingswood","year":"2016","journal-title":"Nephron"},{"issue":"11","key":"10.1053\/j.ajkd.2023.04.016_bib3","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00467-018-4003-6","article-title":"Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study","volume":"33","author":"Janssens","year":"2018","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.04.016_bib4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2015.05.016","article-title":"Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands","volume":"66","author":"Eijkemans","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2023.04.016_bib5","first-page":"1000","article-title":"Effect of everolimus on\u00a0renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2","volume":"34","author":"Bissler","year":"2019","journal-title":"Nephrol Dial\u00a0Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2023.04.016_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"9869","key":"10.1053\/j.ajkd.2023.04.016_bib7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2023.04.016_bib8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/ndt\/gfu013","article-title":"The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1","volume":"29","author":"Kingswood","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2023.04.016_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 Study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1053\/j.ajkd.2023.04.016_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180939","article-title":"Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study","volume":"12","author":"Bissler","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1053\/j.ajkd.2023.04.016_bib11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2023.04.016_bib12","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.ajkd.2023.04.016_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1750-1172-7-87","article-title":"Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial","volume":"7","author":"Cabrera-L\u00f3pez","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2023.04.016_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"issue":"5","key":"10.1053\/j.ajkd.2023.04.016_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrneph.2014.31","article-title":"Novel targets of antifibrotic and anti-inflammatory treatment in CKD","volume":"10","author":"Decl\u00e8ves","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2023.04.016_bib16","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI44774","article-title":"Role of mTOR in podocyte function and diabetic nephropathy in humans and mice","volume":"121","author":"G\u00f6del","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1053\/j.ajkd.2023.04.016_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2022042857","article-title":"Progress in tuberous sclerosis complex renal disease","volume":"27","author":"Bissler","year":"2022","journal-title":"Crit Rev Oncog"},{"issue":"2","key":"10.1053\/j.ajkd.2023.04.016_bib18","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13983","article-title":"Tuberous sclerosis complex exhibits a new renal cystogenic mechanism","volume":"7","author":"Bissler","year":"2019","journal-title":"Physiol Rep"},{"issue":"4","key":"10.1053\/j.ajkd.2023.04.016_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000522226","article-title":"Genetic etiologies for chronic kidney disease revealed through next-generation renal gene panel","volume":"53","author":"Bleyer","year":"2022","journal-title":"Am J Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623007448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623007448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:50:21Z","timestamp":1759463421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638623007448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0272638623007448"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2023.04.016","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2023.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}